ATE432689T1 - Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid - Google Patents

Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid

Info

Publication number
ATE432689T1
ATE432689T1 AT03721329T AT03721329T ATE432689T1 AT E432689 T1 ATE432689 T1 AT E432689T1 AT 03721329 T AT03721329 T AT 03721329T AT 03721329 T AT03721329 T AT 03721329T AT E432689 T1 ATE432689 T1 AT E432689T1
Authority
AT
Austria
Prior art keywords
sustained release
patient
formulations containing
release drug
drug formulations
Prior art date
Application number
AT03721329T
Other languages
English (en)
Inventor
Jacques-Pierre Moreau
Roland Cherif-Cheikh
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE432689T1 publication Critical patent/ATE432689T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03721329T 2002-03-04 2003-03-04 Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid ATE432689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36159202P 2002-03-04 2002-03-04
PCT/US2003/006676 WO2003075887A1 (en) 2002-03-04 2003-03-04 Sustained release drug formulations containing a carrier peptide

Publications (1)

Publication Number Publication Date
ATE432689T1 true ATE432689T1 (de) 2009-06-15

Family

ID=27805051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721329T ATE432689T1 (de) 2002-03-04 2003-03-04 Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid

Country Status (15)

Country Link
US (1) US7943575B2 (de)
EP (1) EP1480618B1 (de)
JP (1) JP2005525374A (de)
KR (1) KR20040091100A (de)
CN (1) CN1638732A (de)
AT (1) ATE432689T1 (de)
AU (1) AU2003224649B2 (de)
BR (1) BR0308137A (de)
CA (1) CA2474613A1 (de)
DE (1) DE60327843D1 (de)
ES (1) ES2327913T3 (de)
MX (1) MXPA04008240A (de)
NO (1) NO20043871L (de)
RU (1) RU2004129577A (de)
WO (1) WO2003075887A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
WO2004057959A2 (en) * 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
EA201001086A1 (ru) 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
NZ553587A (en) * 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
PL2034951T3 (pl) * 2006-06-22 2013-06-28 Biocompatibles Uk Ltd Produkt farmaceutyczny ulegający rehydratacji
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
EP3718557A3 (de) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
JP6134050B2 (ja) * 2013-03-14 2017-05-24 マサチューセッツ インスティテュート オブ テクノロジー ヒト抗体の長期間持続放出のための多層注射可能自己組織化ペプチドスキャホールドヒドロゲル
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
EP3764988A4 (de) * 2018-03-15 2022-04-20 Adepthera LLC Gelbildende polypeptide
CN111195348A (zh) * 2018-11-19 2020-05-26 南京济群医药科技股份有限公司 一种生长抑素纳米混悬剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3484951D1 (de) 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
ATE87469T1 (de) * 1985-12-27 1993-04-15 Sumitomo Pharma Verfahren zur herstellung einer formulierung mit verzoegerter freisetzung.
US4863736A (en) 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
GB2239178B (en) 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
GB8813339D0 (en) 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
US5252565A (en) * 1990-04-02 1993-10-12 Merrell Dow Pharmaceuticals Inc. Haloethyl-substituted steroid enzyme inhibitors
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
EP0930876B2 (de) 1996-07-22 2010-07-07 Renovo Limited Verwendung von substanzen, die die östrogen wirkung fördern, zur beschleunigung der heilung von hautwunden
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors

Also Published As

Publication number Publication date
EP1480618B1 (de) 2009-06-03
ES2327913T3 (es) 2009-11-05
US20050130900A1 (en) 2005-06-16
KR20040091100A (ko) 2004-10-27
BR0308137A (pt) 2005-01-04
MXPA04008240A (es) 2004-12-07
NO20043871L (no) 2004-09-15
AU2003224649B2 (en) 2006-09-07
CA2474613A1 (en) 2003-09-18
AU2003224649A1 (en) 2003-09-22
JP2005525374A (ja) 2005-08-25
EP1480618A1 (de) 2004-12-01
DE60327843D1 (de) 2009-07-16
US7943575B2 (en) 2011-05-17
RU2004129577A (ru) 2005-04-10
WO2003075887A1 (en) 2003-09-18
CN1638732A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ATE504288T1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
EP1242013A4 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
DK1173178T3 (da) Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
ATE298562T1 (de) Hydrogelpartikel formulierungen
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NZ507203A (en) Use of dexmedetomidine for ICU sedation
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
SE9301877D0 (sv) In situ gel for therapeutic use
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
CA2492378A1 (en) Modified amino acid for the inhibition of platelet aggregation
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
EP1582220A1 (de) Zusammensetzung für lokalanästhesie
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties